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INTRODUCTION.
The present research project is designed to reach a complete preclinical characterization (formulation studies, pharmacokinetics analysis, toxicology profile and identification and validation of suitable biomarkers) of Gamitrinib (GA mitochondrial matrix inhibitor), a first-in-class, mitochondrial-targeted small molecule inhibitor of Heat Shock Protein-90 (Hsp90) chaperones. Extensive preliminary data in support of the application have demonstrated that Gamitrinib has a unique mechanism of action, penetrating the mitochondria and selectively inhibiting the ATPase activity of a pool of Hsp90 and Hsp90-homolog TRAP-1 (TNFR-Associated Protein-1, TRAP-1) chaperones localized within the mitochondrial matrix and inner membrane. In turn, this causes catastrophic loss of protein folding quality control selectively within mitochondria, collapse of tumor bioenergetics, massive activation of apoptosis and potent single-agent and combination cytotoxic anticancer activity, in vivo. As Hsp90 chaperones are selectively enriched in tumor mitochondria, as opposed to normal tissues, Gamitrinib has shown good tolerability in preclinical xenograft and genetic tumor models, in vivo. The overarching goal of the proposal is to complete all of the preclinical characterization of Gamitrinib in order to support filing of an Investigational New Drug (IND) Application with the US Food and Drug Administration (FDA). This will fulfill key regulatory requirements in anticipation of the clinical testing of Gamitrinib in patients with advanced, castrate-resistant and metastatic prostate cancer.
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ACCOMPLISHMENTS.  What were the major goals and objectives of the project?
Consistent with the mechanism of anticancer activity of Gamitrinib, which involves disabling of mitochondrial bioenergetics (i) and activation of mitochondrial apoptosis (ii), the major goal of this project for months 0-12 of the award was: To develop a proteomics and metabolomics biomarker of Gamitrinib mitochondriotoxic therapy, in vivo. This included the specific objectives of: Identification of proteomics and metabolomics signatures as a biomarker of Gamitrinib anticancer activity (i), and Evaluation of proteomics and metabolomics signatures as biomarkers of Gamitrinib anticancer activity, in vivo (ii). 
Specific objectives. Subtask 1 -Proteomics identification of mitochondrial proteins that require Hsp90 for proper folding (Mitochondrial Hsp90 Proteome).
To carry out these studies, we first optimized a new biochemical method to detect proteins that require mitochondrial Hsp90 chaperone activity for proper folding and/or stability. For these experiments, we exposed androgenindependent prostate cancer PC3 cells to non-toxic concentrations of Gamitrinib (1-5 M) or vehicle (DMSO), isolated mitochondrial proteins, and treated the samples with increasing detergent concentrations (CHAPS or NP-40) followed by quantification of soluble/insoluble material by SDS-PAGE and Western blotting. After validation of the method, unknown proteins remaining in the insoluble fractions in response to Gamitrinib treatment (i.e., aggregated and misfolded proteins) were identified by 1D proteomics.
As an independent approach to comprehensively map a "mitochondrial Hsp90 proteome", we also optimized a new proteomics approach using Stable Isotope Labeling of Amino Acids in Culture (SILAC). For these experiments, we labeled control or Gamitrinib-treated prostate cancer PC3 cells with heavy and light atoms, mixed the two differentially labeled cultures together and identified differentially represented proteins by unbiased proteomics. Using a highly stringent cutoff of 3-fold differences in protein folding/aggregation between control and Gamitrinib treatment, these two complementary proteomics approaches allowed the identification of 44 proteins in mitochondria that required Hsp90 and TRAP-1 chaperone activity for proper folding, stability and function.
Subtask 2 -Metabolomics screening of mitochondrial Hsp90-directed bioenergetics. Consistent with the SOW, we carried out additional experiments to identify a global metabolomics signature as a biomarker of Gamitrinib inhibition of tumor bioenergetics. For these studies, we incubated androgen-independent prostate cancer PC3 cells with non-cytotoxic concentrations of Gamitrinib (1-5 M) or vehicle (DMSO), and treated cells were analyzed in a global metabolomics screen that quantifies changes in expression levels of 301 metabolites intercalated in various cellular bioenergetics pathways.
Major task 2. Evaluation of proteomics and metabolomics signatures as biomarkers of Gamitrinib anticancer activity, in vivo.
To validate the suitability of changes in tumor bioenergetics as a biomarker of Gamitrinib anticancer activity, in vivo, we carried out studies in a genetic model of prostate cancer using immunocompetent TRAMP (Transgenic Adenocarcinoma of the Mouse Prostate) mice. For these experiments, TRAMP mice were divided into two age groups to received Gamitrinib monotherapy at 5 mg/kg in cremophor as i.p. injections, with the schedule 3 days on/2 days off. Mice in group 1 (short-term treatment) received Gamitrinib starting at 21.9 weeks of age for 3 weeks (24.9 weeks of age), with analysis of primary and metastatic prostate cancer as end point. Animals in group 2 (long-term treatment) were started on Gamitrinib at 14.7 weeks of age for 5 weeks (19.7 weeks of age), and assessed histologically for primary prostate cancer growth, development of prostatic intraepithelial neoplasia (PIN), localized inflammation and expression of a combined biomarker signature of metabolic starvation, cellular stress response and autophagy. These experiments were partially supported by the present award.
To further characterize the role of mitochondrial Hsp90 chaperones as targets of Gamitrinib anticancer activity, we generated TRAP-1 knockout mice. Using gene-trap technology, we obtained mouse ES cells in which a β-galactosidase gene disrupts the TRAP-1 locus on chromosome 16, downstream of exon 1. Transfer of TRAP-1-targeted zygotes into C57Bl/6 pseudopregnant recipient mice generated TRAP-1 knockout animals. In genotyping experiments, PCR products of 565 nt, or, conversely, 1,148 nt identified the wild-type (WT) TRAP-1 allele or the β-galactosidase (LacZ)-containing allele, respectively. TRAP-1 knockout (TRAP-1 −/− ) mice were born viable, fertile, and at expected Mendelian rates for both genders. Analysis of tissues from TRAP-1 −/− mice, including liver, kidney, uterus, spleen, brain, heart, and testis confirmed the absence of TRAP-1 protein, compared to WT littermates, by Western blotting. Control and TRAP-1 -/-mice were extensively analyzed for mitochondrial and bioenergetics functions. These experiments were partially supported by the present award. These experiments were partially supported by the present award.
Significant results or key outcomes.
Using the combined studies of 1D and SILAC proteomics, we identified a discrete "mitochondrial Hsp90 proteome" comprising molecules that require the chaperone activity for proper folding and activity. These proteins were intercalated in virtually every mitochondrial function, and comprised transcription factors TFB1M and TFB2M involved in mitochondrial gene expression and glucose homeostasis, ribosomal proteins associated with RNA translation (MRPLs, MTG1, ERAL1), regulators of purine biosynthesis and the methyl cycle (MTHFD2), and effectors of oxidative phosphorylation, including SDHB, IDH3G, NDUFS3, PDHB, MDH2. Mitochondrial proteins participating in redox status and detoxification pathways (PRDX6, POLDIP2, CYB5R1, ETHE1) were also identified in the mitochondrial Hsp90 proteome ( Figure 1 ).
Figure 1. Proteomics identification of the mitochondrial Hsp90 proteome as the target of Gamitrinib anticancer activity.
See text for description of specific mitochondrial proteins that require Hsp90/TRAP-1 chaperone activity for stability and/or function.
To validate experimentally the mitochondrial Hsp90 proteome, we next carried out a global metabolomics screen of Gamitrinib-treated PC3 cells. In these experiments, Gamitrinib caused global bioenergetics defects compared to vehicletreated cultures. These included aberrant accumulation of citric acid cycle metabolites, succinate, fumarate and malate, pointing to extensive defects in oxidative phosphorylation (Figure 2 ), deregulated fatty acid metabolism, leading to increased long chain fatty acid transport into mitochondria, aberrations in branched chain amino acid metabolism, and changes in redox status ( Figure 2 ). Gamitrinib-targeted cells exhibited additional defects in the metabolism of cholesterol, purine, and arginine processing ( Figure 2 ). Consistent with induction of metabolic starvation, Gamitrinib treatment increased the AMP/ATP ratio in prostate cancer cells, induced phosphorylation of the energy sensor, AMP-activated kinase (AMPK), a key marker of cellular starvation, and inhibited mammalian target of Rapamycin (mTORC1) signaling ( Figure  2 ). Consistent with the ability of Gamitrinib to induce a phenotype of metabolic starvation with activation of AMPK and stimulation of autophagy, we next carried out in vivo studies in Gamitrinib-treated TRAMP mice. In this model, fully immunocompetent TRAMP mice express the large T antigen oncogene in the prostatic epithelium under the control of the probasin promoter and develop prostatic intraepithelial neoplasia (PIN), invasive prostate cancer and metastatic disease. Systemic treatment with Gamitrinib inhibited localized and metastatic prostate cancer in TRAMP mice. In addition, histological analysis confirmed that Gamitrinib-treated TRAMP mice exhibited a biomarker signature of cellular starvation, with increased expression of phosphorylated AMPK (Thr172) (i), induction of autophagy based on conversion of the dynamin light chain 3 (LC3-II) protein to a lipidated form (ii), and upregulation of the endoplasmic reticulum (ER) stress marker, Grp78 (iii) (Figure 3 ).
Figure 3.
Characterization of a Gamitrinib biomarker signature of anticancer activity, in vitro. TRAMP mice were treated systemically with Gamitrinib with the 3 days/2 days off schedule, and tissues were analyzed histologically for changes in expression of phosphorylated (p) AMPK (top), ER stress marker, Grp78 (middle) or autophagy (LC3-II conversion, bottom). Right panels, quantification of immunohistochemistry score for the indicated markers.
To further characterize the impact of mitochondrial Hsp90s in cellular bioenergetics, in vivo, we next generated mice deficient in TRAP-1. This is a mitochondrial-localized Hsp90-like chaperone targeted by Gamitrinib, and contributing to organelle homeostasis. TRAP-1 knockout mice were born viable, fertile and at expected Mendelian rates for both genders. However, TRAP-1 deletion resulted in major compensatory responses in targeted mice characterized by transcriptional upregulation of virtually every metabolic effector of oxidative phosphorylation and glycolysis. In turn, this resulted in aberrantly increased oxidative phosphorylation, deregulated cellular respiration, higher production of reactive oxygen species (ROS) and a general bioenergetics switch towards anaerobic glycolysis. This phenotype of metabolic reprogramming was dramatically evident when wild type (WT) and TRAP-1 knockout mice were analyzed by 18 F-FDG Positron Emission Tomography (PET). In these experiments, TRAP-1 knockout mice exhibited a 2-to 3-fold increase in standardized uptake values (SUVs) of the radioactive tracer in the liver, compared to WT littermates, as determined 1 h postinjection of 18 F-FDG ( Figure 4 ). 
4.
Other achievements. More recent experiments expanded the preclinical characterization of Gamitrinib in anticipation of combination anticancer regimens in prostate cancer. In these studies, we performed a high-throughput drug combination screen, and demonstrated that Gamitrinib potently and selectively synergized with small molecule inhibitors of the PI3K/Akt/mTOR pathway currently in clinical trials. The molecular basis for this synergistic effect is under investigation and evidence points to a role of adaptive mitochondrial reprogramming in conferring resistance to PI3K therapy. Conversely, Gamitrinib treatment abolishes the compensatory response of mitochondrial adaptation and restores the sensitivity of tumor cells to PI3K therapy. In xenograft models, the combination of Gamitrinib plus PI3K therapy strongly inhibited tumor growth with minimal systemic or organ toxicity. A new manuscript describing these findings has been submitted for consideration (Ghosh et al, 2014) , and is currently under review.
 What opportunities for training and professional development has the project provided?
The present application was not designed to provide a training and professional development environment. Nothing to report.
 How were the results disseminated to communities of interest? The findings described above were disseminated through publication of two research articles in the peer-reviewed, premiere biomedical literature (Nature Comm; Cell Reports); one oral presentation at a national conference (Keystone Conference on Mitochondrial Dynamics and Physiology, Santa Fe, NM -18/2/2014 -23/2/2014); and submission for publication of a new manuscript describing the synergy between Gamitrinib and PI3K/Akt/mTOR small molecule antagonists currently in clinical development.
 What do you plan to do during the next reporting period to accomplish the goals? During the next reporting period, we will pursue the experimental tasks set forth in the SOW of the present application. As a global metabolomics and biomarker signature for the anticancer activity of Gamitrinib has now been validated, we will determine the optimal formulation requirements of Gamitrinib (i), validate an HPLC-based method for the detection of Gamitrinib in plasma (ii), reach a comprehensive pharmacokinetics profile of Gamitrinib administration in vivo (iii), and begin IND-enabling toxicology, toxicokinetics and pharmacodynamics studies of systemic Gamitrinib therapy, in vivo (iv).
IMPACT
 What was the impact on the development of the principal disciplines of the project? The results outlined above have significant impact for the experimental and medical fields of tumor metabolic reprogramming (i), rewiring of mitochondrial functions in cancer (ii), and opportunities for molecular therapy created by targeting these pathways (iii). Although tumor metabolism is a validated therapeutic target in cancer, the identification and preclinical development of small molecule antagonists of these pathways for cancer therapy have not been widely reported. Our findings that Gamitrinib therapy induces major metabolic defects in tumor cells (i), that these changes provide reproducible biomarkers of anticancer activity in genetic models of prostate cancer (ii), and that targeting these mechanisms results in potent anticancer activity in single agent or combination regimens, in vivo, establish a pivotal, first-in-class proof of concept. As a result of our studies, targeting mitochondrial bioenergetics for cancer therapy is now proven feasible, supported by validated companion biomarkers of metabolic imbalance in immunocompetent tumor models. In terms of drug development, these findings further validate the rationale for the preclinical development of Gamitrinib in anticipation of human testing as a first-in-humans therapeutic approach to target aberrant tumor metabolic reprogramming in prostate cancer patients.
 What was the impact on other disciplines? The results above have also relevance for other experimental fields of biochemistry and molecular biology, advancing our understanding of regulatory mechanisms of bioenergetics. Although the function of oxidative phosphorylation has long been established, the identification of a key role of Hsp90 chaperonedirected protein folding as a prerequisite for cellular respiration has not been previously appreciated. Second, our identification of a mitochondrial Hsp90 proteome that oversees virtually every organelle function suggests that Hsp90-directed protein folding plays a pivotal role in maintaining mitochondrial homeostasis. Finally, our data demonstrate that mitochondrial bioenergetics is not a static process, but continuously undergoes flexible modulation and adaptation in response to cellular stress, relying on transcriptional regulation of oxidative phosphorylation and glycolysis effectors, as reflected by the compensatory and adaptive phenotypes of TRAP-1 knockout mice.
 What was the impact on technology transfer? Nothing to report.
 What was the impact on society beyond science and technology? Nothing to report.
CHANGES/PROBLEMS.
 Changes in approach. We do not anticipate any changes in approach for the further preclinical development of Gamitrinib. The results reported above provide an ideal mechanistic foundation for the further characterization of Gamitrinib's drug formulation, HPLC-based detection in plasma, pharmacokinetics, and toxicology.
 Actual or anticipated problems or delays and actions or plans to resolve them. We do not anticipate problems or delays in carrying out and successfully accomplish the milestones set forth in the year 2 of the SOW for the present application.
 Changes that had a significant impact on expenditures. None reported.
 Significant changes in use or care of human subjects, vertebrate animals, biohazards, and/or select agents. None reported. Dr. Ghosh conducted a high-throughput drug screening to characterize the preclinical activity of Gamitrinib in combination with other molecular therapies, and the role of mitochondria in adaptive reprogramming to small molecule PI3K antagonists. Funding Support:
PRODUCTS
In addition to the present award, these studies are also supported by NIH NCI CA78810 and CA140043. There is no scientific or budgetary overlap between any grants listed.
 Has there been a change in the active other support of the PD/PI(s) or senior/key personnel since the last reporting period? Nothing to report.
R eprogramming of tumour cell metabolism 1 is increasingly recognized as a multifaceted disease driver, enhancing biomass expansion 2 , and promoting various mechanisms of oncogenic signalling 3 . Although these processes have been mostly studied in the context of aerobic glycolysis, the so-called Warburg effect 3 , there is evidence that mitochondria continue to have an important role in tumour metabolism 4, 5 , and organelle-driven oxidative phosphorylation has been associated with tumorigenic potential 6 , drug resistance 7, 8 and enhanced tumour cell survival 9 . Harnessing these pathways may open new prospects for cancer therapy 10 , but the regulators of mitochondrial homeostasis in tumours have remained largely elusive, and their potential suitability as drug candidates is unknown.
With a complex, multi-compartment topology, dependence on import of nuclear-encoded proteins and production of proteinmodifying reactive oxygen species (ROS), mitochondria must tightly control their protein folding environment 11 . This is indispensable to maintain metabolic output 2 , ensure organelle integrity 12 and prevent the consequences of an unfolded protein response, which may result in cell death 13 . Buffering mitochondrial proteotoxic stress, especially in the protein-dense and energy-producing organelle matrix 14 , relies on adaptive responses mediated by molecular chaperones and AAA proteases 15 , and dysregulation of these mechanisms has been linked to human diseases, including neurodegeneration and cancer 14 .
In this context, a pool of ATPase-directed molecular chaperones, including heat shock protein 90 (Hsp90) 16 and its related homologue, TNF receptor-associate protein-1 (TRAP-1) 17 localize to the mitochondria, almost exclusively in tumour cells 18 . The molecular requirements for the selective accumulation of these chaperones in tumour mitochondria have not been completely elucidated. However, there is evidence that both Hsp90 and TRAP-1 form overlapping complexes with mitochondrial proteins, including cyclophilin D (CypD), a component of the permeability transition pore and control their folding 19 . Accordingly, inhibition of Hsp90 and TRAP-1 chaperone activity selectively in mitochondria triggered acute organelle dysfunction 20 , defective hexokinase II (HK-II)-dependent 2 ATP production 21 , and anticancer activity in preclinical tumour models, in vivo 19 .
In this study, we examined the role of Hsp90-directed mitochondrial protein folding on cellular homeostasis. Using combined proteomics and metabolomics approaches, we found that mitochondrial Hsp90 and TRAP-1 are global regulators of tumour metabolic reprogramming, including oxidative phosphorylation, and are required for disease maintenance.
Results
Identification of a mitochondrial Hsp90 proteome. We began this study by setting up a preliminary proteomics screen to identify regulators of mitochondrial protein homeostasis, or proteostasis, in tumours. For these experiments, we used noncytotoxic concentrations of Gamitrinib (GA mitochondrial matrix inhibitor), a mitochondrial-targeted, small molecule ATPase antagonist that inhibits the chaperone activity of both Hsp90 and TRAP-1 in tumours 20 .
Treatment of glioblastoma LN229 cells with non-cytotoxic concentrations of Gamitrinib 21 caused the accumulation of aggregated and misfolded proteins, characterized by resistance to detergent solubilization ( Supplementary Fig. S1 ). Preliminary mass spectrometry analysis of selected bands showing higher intensities with Gamitrinib treatment identified 96 mitochondrial proteins (Supplementary Data 1). Forty-four of these proteins based on spectral counts were elevated by more than threefold after Gamitrinib treatment, indicating a requirement of Hsp90 for their folding. Although gel-based comparison ( Supplementary  Fig. S1 ) provides high detection sensitivity for specific bands, individual bands are not single proteins, and slight differences in band excision between control and Gamitrinib treatment can produce artificial differences. To minimize this concern, this experiment focused primarily on band differences at the 2% CHAPS condition, where protein complexity was the lowest, but not necessarily where the largest fold change occurred. To independently validate these initial results, we next performed unbiased proteomics studies using stable isotope labelling by amino acids in culture (SILAC) of control or Gamitrinib-treated cells. Of the original 44 proteins of the mitochondrial Hsp90 proteome identified by 1D mass spectrometry, 33 were independently confirmed for response to Gamitrinib in SILAC experiments (Fig. 1a) . Of the remaining 11 proteins, 7 were below adequate detection levels for SILAC quantification, and 4 did not show significant changes.
These verified mitochondrial Hsp90-regulated proteins ( Fig. 1a and Supplementary Table S1) comprised the following: transcription factors TFB1M and TFB2M involved in organelle gene expression 22 and glucose homeostasis 23 ; ribosomal proteins (MRPLs, MTG1 and ERAL1) associated with RNA translation [24] [25] [26] ; regulators of purine biosynthesis and the methyl cycle (MTHFD2) 27 ; and effectors of oxidative phosphorylation 2 , including SDHB, IDH3G, NDUFS3, PDHB and MDH2 (ref. 28) (Fig. 1b) . Mitochondrial proteins participating in redox status and detoxification pathways (PRDX6, POLDIP2, CYB5R1 and ETHE1) [29] [30] [31] were also identified in the mitochondrial Hsp90 proteome (Fig. 1b) .
Mitochondrial Hsp90 regulation of tumour metabolism. The impact of a mitochondrial Hsp90 proteome (Fig. 1b) on cellular homeostasis was next investigated. For these experiments, we quantified the level of 301 individual metabolites in prostate adenocarcinoma PC3 cells treated with non-cytotoxic concentrations of Gamitrinib 21 or, alternatively, silenced for expression of TRAP-1 by small interfering RNA (siRNA) 21 . Both approaches produced global defects in tumour cell metabolism (Supplementary Data 2). Consistent with a requirement of Hsp90 for oxidative phosphorylation (Fig. 1b) , Gamitrinib-treated cells exhibited aberrant accumulation of citric acid cycle metabolites, succinate, fumarate and malate (Fig. 2a) . This was associated with altered glutaminolysis (elevation in glutamine and a-ketoglutarate) ( Supplementary Fig. S2 ) and deregulated fatty acid metabolism (Fig. 2b) , leading to higher levels of palmitate and linoleate, increased long chain fatty acid transport into mitochondria (elevation of palmitoylcarnitine and stearoylcarnitine), and excess lipid oxidation (accumulation of the ketone body 3-hydroxybutyrate ( Supplementary Fig. S3 ). Mitochondrial Hsp90-targeted cells also showed increased AMP/ATP ratio ( Supplementary Fig. S3 ), indicative of cellular starvation, and consistent with the loss of ATP production, phosphorylation of the energy sensor, AMP-activated kinase (AMPK), and inhibition of mammalian target of Rapamycin complex (mTORC1) observed in response to Gamitrinib 21 .
Targeting mitochondrial Hsp90s impaired the catabolism of branched-chain amino acids, with accumulation of valine, isoleucine and leucine (Fig. 2c) , and decreased levels of branched-chain amino acid catabolites, isobutyryl-carnitine, succinylcarnitine, 2-methylbutyryl-carnitine and isovaleryl-carnitine (Fig. 2c, Supplementary Fig. S4 ). This was associated with defects in redox status (Fig. 2d) , cholesterol homeostasis (Fig. 2e) and purine nucleotide metabolism (Fig. 2f) , resulting in higher levels of cholesterol metabolites associated with lipid peroxidation, ROS-dependent allantoin generation (Fig. 2f,  Supplementary Fig. S5 ), and increased oxidized glutathione, cysteine-glutathione disulphide and the glutathione catabolic product, 5-oxoproline ( Supplementary Fig. S6 ). Increased ROS production under these conditions may result from dysfunctional mitochondrial metabolism (see above), and/or increased nitric oxide generation from arginine, a possibility suggested by the accumulation of citrulline under these conditions (Fig. 2g,  Supplementary Fig. S7 ).
Overall, Gamitrinib treatment produced more extensive changes in the tumour metabolome, compared with siRNA silencing of TRAP-1 ( Fig. 2 and Supplementary Figs S2-S7 ). This may reflect incomplete TRAP-1 knockdown by siRNA, or, alternatively, compensatory mechanisms provided by mitochondrial Hsp90, which is inhibited by Gamitrinib, but not by TRAP-1 knockdown. As a control, treatment of PC3 cells with 17-allylamino 17-demethoxygeldanamycin (17-AAG), which inhibits Hsp90 in the cytosol, but not mitochondria 20 , or transfection of a control, non-targeting siRNA, had minimal effects on metabolic pathways (Supplementary Figs S2-7) . In previous experiments, addition of the triphenylphosphonium 'mitochondriotropic' moiety, alone or in the presence of 17-AAG, had no effect on mitochondrial function 20 .
Mechanism of mitochondrial Hsp90 control of tumour metabolism. To elucidate how mitochondrial Hsp90s regulate tumour bioenergetics, we next focused on SDHB, the iron-sulphur subunit of ETC Complex II 32 , which required Hsp90s for proper folding (Fig. 1a,b , Supplementary Table S1, Supplementary Data 1), and functional activity ( Supplementary Fig. S2 ). Treatment of tumour cells with Gamitrinib caused insolubility of Complex II over a range of detergent concentrations ( Fig. 3a and Supplementary Fig. S8a ). In contrast, mitochondrial proteins comprising other ETC Complexes (I, IV, III and V) were minimally affected (Fig. 3a) . Immune complexes precipitated from mitochondrial fractions of tumour cells with two independent antibodies to SDHB, but not control IgG, contained TRAP-1, in vivo ( Supplementary Fig. S8b ). In addition, immunoprecipitated SDHB associated with recombinant TRAP-1, in vitro ( Supplementary Fig. S8c ), demonstrating that these two proteins interact in tumour mitochondria. Suggestive of a chaperone-'client protein' recognition 33 , this interaction was required to preserve SDHB stability, as Gamitrinib treatment (Fig. 3b) , or siRNA silencing of TRAP-1 ( Supplementary Fig.  S8d ) caused SDHB degradation in tumour cells (Fig. 3c) .
We next asked whether a TRAP-1-SDHB complex was important during cellular stress. In control experiments, exposure of tumour cells to concentrations 450 mM of the oxidative agent, hydrogen peroxide (H 2 O 2 ), reduced SDHB levels (Fig. 3d) . siRNA silencing of TRAP-1 exacerbated this response and induced nearly complete loss of SDHB expression at lower H 2 O 2 concentrations (Fig. 3d) . As a control, the expression of the flavoprotein subunit of Complex II, SDHA 28 , was not affected (Fig. 3d) . Functionally, treatment of tumour cells with Gamitrinib inhibited Complex II activity in a concentration-dependent manner, whereas 17-AAG had no effect (Fig. 3e) . Reciprocally, addition of recombinant TRAP- 1   SDHB  CLPP  IDH3G  ERAL1  ECHS1  C1QBP  MRPL3  MRPL9  MRPL44  MRPL24  MRPL19  MRPS34  MRPS2  MRPS7  MRPS5  TFB2M  POLDIP2  MRPS9  MTHFD2  MRPL38  MRPS22  MRPS18B  NIPSNAP1  MRPS27  LDHB  MRPL4  MRPS35  PRDX6  NDUFS3  ETFA  MRPL16  RDH14  MRPL10 Gamitrinib Control to SDHB immuno-affinity isolated from mitochondrial extracts enhanced Complex II activity in a concentration-dependent manner, in vitro (Fig. 3f) .
Mitochondrial Hsp90 regulation of bioenergetics stress. The results above have suggested that Hsp90-directed protein folding preserves the stability and function of SDHB in tumour cells. To determine whether this mechanism regulates oxidative phosphorylation, we next quantified the respiration rates of tumour cells in real time. At the same concentrations that induce SDHB misfolding (Fig. 3a) , and impaired mitochondrial metabolism (Figs 1,2) , Gamitrinib inhibited the oxygen consumption rate (OCR) in prostate PC3 cancer (Fig. 3g,h, Supplementary Fig.  S9a ), or glioblastoma LN229 ( Supplementary Fig. S9b-d ) cells, in a concentration-dependent manner. 17-AAG had no effect on OCR (Fig. 3g,h, Supplementary Fig. 9 ). siRNA knockdown of TRAP-1 in PC3 (Fig. 3i,j, Supplementary Fig. S10a ), or LN229 ( Supplementary Fig. S10b-d ) cells, partially attenuated the inhibition of OCR mediated by Gamitrinib, compared with control transfectants. In contrast, transfection of tumour cells with nontargeting siRNA had no effect on OCR, with or without Gamitrinib (Fig. 3i,j, Supplementary Fig. S10a-d) . The partial reduction in the respiratory capacity and SDHB inhibition produced by Gamitrinib when added after siRNA silencing of TRAP-1, as compared with the near complete inhibition observed when Gamitrinib is added without prior siRNA to TRAP-1, may reflect a compensatory protective response by the mitochondria as a result of the extended partial TRAP-1 inhibition produced by siRNA knockdown of TRAP-1, potentially involving organelle Hsp90.
Most tumours undergo metabolic reprogramming, and utilize aerobic glycolysis as their main energy source 3 . Therefore, we asked whether oxidative phosphorylation enabled by Hsp90-directed protein folding was important for tumour maintenance. Tumour cells transfected with control siRNA and maintained in abundant nutrients (10 mM glucose) exhibited normal cellular respiration (Fig. 4a,b, Supplementary Fig. S10e ). This response was increased at lower glucose concentrations (1 mM), suggestive of a compensatory mechanism that elevates ATP output by oxidative phosphorylation during nutrient deprivation (Fig. 4a,b,  Supplementary Fig. S10e ). Under these experimental conditions, siRNA knockdown of TRAP-1 abolished the compensatory increase in OCR at limiting glucose concentrations (1 mM), whereas cellular respiration in 10 mM glucose was minimally affected (Fig. 4a,b, Supplementary Fig. S10e) . In reciprocal experiments, we transfected a control plasmid or TRAP-1 cDNA in normal NIH3T3 fibroblasts (Fig. 4c) , which have low endogenous levels of mitochondrial Hsp90 and TRAP-1 (ref. 18) . NIH3T3 fibroblasts transfected with control cDNA exhibited reduced ATP production (Fig. 4c) , and phosphorylation of AMPK (Fig. 4d) at limiting glucose concentrations, consistent with cellular starvation. In contrast, transfection of TRAP-1 restored ATP production (Fig. 4c) , and reduced AMPK phosphorylation (Fig. 4d) at low glucose concentrations. of hypoxia-inducible factor-1a (HIF-1a) (Fig. 5a ), an oncogenic transcription factor implicated in adaptive responses to cellular stress 34 . Inhibition of mitochondrial Hsp90s with Gamitrinib ( Fig. 5b) , or siRNA silencing of TRAP-1 (Fig. 5c ), was insufficient, alone, to modulate HIF-1a levels, whereas both treatments strongly enhanced TTFA induction of HIF-1a in tumour cells (Fig. 5b,c) . In parallel experiments, tumour cells exposed to hypoxia exhibited increased recruitment of Hsp90 to mitochondria, compared with cytosol ( Fig. 5d,e) , and this response was reversed by HIF-1a silencing by siRNA (Fig. 5f,g ). The mitochondrial pool of HK-II was also increased under hypoxic conditions (Fig. 5d,e) , and this response was also abolished by siRNA knockdown of HIF-1a (Fig. 5f,g ). In contrast, normoxic conditions (Fig. 5d,e) , or transfection of tumour cells with non-targeting siRNA (Fig. 5f,g ) had no effect. Mutations in Complex II 35 , including SDHB 36 , have been linked to hereditary or sporadic pheochromocytoma (PCC) 37 , and paraganglioma (PGL) 38 , potentially through a mechanism of HIF-1a-dependent tumorigenesis 39 . Consistent with HIF-1a-dependent accumulation of Hsp90 to mitochondria after Complex II inhibition (Fig. 5e,g ), TRAP-1 was strongly expressed in PCC/PGL samples carrying SDHB and SDHD mutations, compared with tumours with mutations in RET, NF1 and VHL, or of unknown genotype (Fig. 5h,i) . Functionally, PCC/ PGL tumours with Complex II mutations and high levels of TRAP-1 (Fig. 5j) were more sensitive to Gamitrinib-mediated killing, in vitro (Fig. 5j) , suggesting a compensatory pro-survival role of mitochondrial Hsp90s in transformed cells with defective oxidative phosphorylation 39 .
Discussion
In this study, we have identified mitochondrial Hsp90s 18 as global regulators of tumour cell metabolism, including oxidative phosphorylation and redox networks. This pathway hinges on chaperone-directed protein folding in mitochondria 15 , and affects a discrete Hsp90/TRAP-1 18 proteome intercalated in multiple, fundamental pathways of cellular homeostasis. This mechanism may be ideally suited to buffer the risk of proteotoxic stress in transformed cells with high biosynthetic needs 19 , preserve organelle integrity against CypD-dependent apoptosis 20 and maintain multiple sources of energy production, including HK-II-dependent glycolysis 21 , and oxidative phosphorylation (this study), especially under stress conditions of hypoxia and nutrient deprivation.
The considerable interest in aerobic glycolysis 3 as a central feature of tumour metabolic reprogramming 1 , together with the signalling role of oncogenes in these responses 40 , have brought into question the function of mitochondrial bioenergetics, and in particular oxidative phosphorylation, in tumour maintenance 28 . However, recent studies have suggested that mitochondrial oxidative phosphorylation continues to remain critical for tumour cells 6 , favouring resistance to therapy 7, 8 and promoting cell survival 9 . The data presented here provide a mechanistic framework in support of these observations, and identify Hsp90/ TRAP-1-directed protein folding in mitochondria 18 as a key requirement of oxidative phosphorylation in tumours. This involved the formation of physical complex(es) between Hsp90/ TRAP-1 and the iron-sulphur subunit of mitochondrial ETC Complex II, SDHB 32 , preserving its folding, stability and enzymatic function under oxidative stress. Functionally, Hsp90/ TRAP-1 regulation of SDHB maintained energy production under conditions of low nutrients and hypoxia, which are hallmarks of tumour growth, in vivo 41 , and dampened biochemical signals of cellular starvation that are typically associated with tumour suppression 42 .
SDHB 32 has attracted attention as a gene mutated in certain human neuroendocrine tumours 36 . The molecular requirements of how these mutations contribute to malignancy are still being worked out 36 , but one consequence of pharmacological or genetic inactivation of SDHB observed here was an increased recruitment of Hsp90 to mitochondria 18 . This pathway required HIF-1a, which is deregulated in SDHB-mutant tumours, and may potentially contribute to disease maintenance 39 . The increased accumulation of mitochondrial Hsp90s under these conditions may help compensate for the impaired oxidative phosphorylation resulting from defective SDHB function 36 , enhancing organelle integrity against CypD-mediated permeability transition 18 and energy production via HK-II-directed glycolysis 21 . Consistent with this model, SDHB-mutant tumour cells were more sensitive to Gamitrinib-mediated killing than other neuroendocrine malignancies, suggesting that Hsp90-directed protein folding in mitochondria provides an adaptive and potentially 'addictive' survival factor for these cells.
There is now intense interest in pursuing aberrant tumour cell metabolism for cancer therapeutics 10 . However, inhibitors that can safely target these pathways in tumours, as opposed to normal tissues, especially with respect to oxidative phosphorylation 7, 8 , have not been clearly identified 43 . As a mitochondrial-directed Hsp90 inhibitor 20 , Gamitrinib may be ideally suited to function as a general antagonist of tumour cell metabolism. Supported by the differential targeting of tumour, as opposed to normal mitochondria 18 , and a favourable safety profile in preclinical models 20 , Gamitrinib inhibition of mitochondrial Hsp90s may simultaneously disable metabolic and survival adaptive networks in genetically heterogeneous tumours. Subcellular fractionation. Mitochondrial fractions were isolated from Gamitrinib-treated LN229 cells (0-20 mM for 5 h) using an ApoAlert cell fractionation kit (Clontech), as described 20 . Briefly, LN229 cells or PC3 cells were mechanically disrupted by 70 strokes with a Dounce homogenizer in isolation buffer containing 1 mM DTT plus protease inhibitor cocktail. Cell debris was removed by centrifugation at 700 g for 10 min. The supernatant was further centrifuged at 10,000 g for 25 min, and supernatants or mitochondrial pellets were processed for further analysis.
Methods
Mitochondrial protein folding. Mitochondrial fractions were isolated from vehicle-or Gamitrinib-treated LN229 cells (5 mM for 12 h), and suspended in equal volume of mitochondrial fractionation buffer containing increasing concentrations of CHAPS (0, 0.05, 0.1, 0.2, 0.5, 1 or 2%). Samples were incubated for 20 min on ice and detergent-insoluble protein aggregates were recovered by centrifugation (20,000 g) for 20 min. Pelleted proteins were separated by SDS-gel electrophoresis and visualized by silver staining (Sigma-Aldrich).
Proteomics studies. To identify mitochondrial proteins that require organelle Hsp90s for proper folding and/or activity (mitochondrial Hsp90 proteome), individual silver-stained bands isolated from mitochondrial fractions of vehicle or Gamitrinib-treated LN229 cells were analysed by 1D MS (see Supplementary Methods). As an independent experimental approach, global proteomics analysis of vehicle or Gamitrinib-treated LN229 cells was carried out by SILAC technology (see Supplementary Methods). Changes in the expression of 301 metabolites were determined by ultrahigh performance liquid chromatography/mass spectroscopy and gas chromatography/mass spectroscopy in PC3 cells treated with vehicle or Gamitrinib (2.5, 5 mM), non-mitochondrial-targeted 17-AAG (5 mM), or alternatively, transfected with control non-targeting or TRAP-1-directed siRNA (see Supplementary Methods).
Purification of TRAP-1 proteins. NIH3T3 cells were transfected with human TRAP-1-Myc plasmid cDNA. After 48 h, cells were washed with PBS and lysed in PBS containing 1% TX-100 plus phosphatase inhibitor cocktail (Roche). Lysates were centrifuged at 14,000 g for 10 min at 4°C, and c-Myc-tagged TRAP-1 proteins were isolated by immunoprecipitation with an antibody to c-Myc coupled to agarose beads (Sigma-Aldrich). Samples were then washed five times with lysis buffer, and TRAP-1-myc was eluted from the immune complex with 100 mg ml À 1 c-Myc peptide (Sigma-Aldrich) in PBS. To eliminate free c-Myc peptide and further enrich eluted TRAP-1-containing material, samples were purified with centrifugal filter (30 K, Millipore).
SDH activity assay. Tumour cells were analysed for SDH complex activity as reduction of the dye 2,6-dichlorophenolindophenol, which recycles the substrate ubiquinone using Complex II enzyme activity. Briefly, mitochondria isolated from PC3 or LN229 cells were lysed in enzyme assay buffer containing 1% N-dodecyl-b-D-maltopyranoside plus protease inhibitors (Roche) for 1 h at 4°C under constant agitation. After centrifugation at 15,000 g for 20 min at 4°C, supernatants were loaded on anti-Complex II antibody-coated 96-well plates, and incubated with increasing concentrations of recombinant TRAP-1 for 2 h. Enzyme activity was determined from SDH-dependent reduction of dye 2,6-dichlorophenolindophenol, and quantified as changes in absorbance at 600 nm for 3 h at 2 min intervals using a plate reader (Beckman Coulter).
Cellular respiration. OCRs were assayed using the Extracellular Flux System 24 Instrument (Seahorse Bioscience, Billerica, MD). PC3 or LN229 cells were grown in standard media and after trypsinization and re-suspension in growth media, 25,000 cells were plated in each well of a Seahorse XF24 cell culture plate (100 ml volume). After 4-h incubation to allow the cells to adhere to the plate, an additional 150 ml of media was added to each well, and the cells were grown for 24 h at 37°C with 5% CO 2 . The media was then exchanged with unbuffered DMEM XF assay media (Seahorse Bioscience) supplemented with 2 mM glutaMAX, 1 mM sodium pyruvate and 5 mM glucose (pH 7.4 at 37°C), and equilibrated for 30 min at 37°C and B0.04% CO 2 before the experiment. Cellular oxygen consumption was monitored in basal condition (before any addition) and after addition of oligomycin (1.25 mM), FCCP (0.4 mM) and antimycin (1.8 mM), all dissolved in DMSO. The three drugs were injected into the XF24 sequentially, and the OCRs measured using the extracellular flux analyser with three cycles of mixing (150 s), waiting (120 s) and measuring (210 s). This cycle was repeated following each injection 44 . To test the effect of mitochondrial Hsp90s on cellular respiration, PC3 or LN229 cells were treated with non-cytotoxic concentrations of Gamitrinib (0-10 mM) or 17-AAG (2.5-5 mM) and continuously analysed for OCR changes. Alternatively, cells were transfected with control or TRAP-1-directed siRNA and analysed after 24-36 h.
Patient samples. All experiments involving patient-derived material were approved by the Tufts Medical Center Institutional Review Board following informed consent. A series of genetically characterized PCC/PGL with documented mutations of major susceptibility genes (n ¼ 10, SDHB; 6 SDHD; 4 VHL; 3 RET; 2 NF1), apparently sporadic PCC/PGL (n ¼ 22) and normal human adrenal medulla was examined in this study. All of the tumours with VHL, RET or NF1 mutations were intra-adrenal, while 10/13 with SDHB, 3/6 with SDHD, and 10/25 with no known mutations were extra-adrenal. Two of the extra-adrenal tumours with SDHD mutations were in the head or neck and the remainder retroperitoneal. For four of the tumours with SDHB mutations, tissue was available only from metastatic sites. One SDHB-mutated tumour was an adrenal bed recurrence of a primary malignancy that had given rise to metastases. All of the other specimens were primary tumours.
Statistical analysis. Data were analysed using the two-sided unpaired t-tests using a GraphPad software package (Prism 4.0) for Windows. Data are expressed as mean±s.d. or mean±s.e.m. of multiple independent experiments. A P-value of o0.05 was considered as statistically significant. For pair-wise comparisons in metabolite screening studies, the Welch's t-tests, Wilcoxon's rank sum tests or ANOVA were performed. For classification studies, random forest analyses were performed. Statistical analyses are performed with the program 'R' http://cran.r-project.org/.
INTRODUCTION
The control of protein folding in subcellular organelles, including mitochondria , maintains cellular homeostasis (Ellis, 2007) by buffering proteotoxic stress and ensuring flexible adaptation to environmental cues (Balch et al., 2008) . In mitochondria, a network of chaperones of the heat shock protein-90 (Hsp90) gene family , including Hsp90 and its related homolog TNFR-associated protein-1 (TRAP-1) (Lavery et al., 2014) , protects against oxidative stress and permeability transition-induced apoptosis (Altieri et al., 2012) . This pathway is exploited in cancer, where mitochondrial Hsp90s are dramatically upregulated, compared to normal tissues .
Recent evidence suggests that mitochondrial Hsp90s may play a more global role in organelle homeostasis. Mechanistically, this involves protein-folding quality control of a discrete mitochondrial Hsp90 proteome, overseeing gene expression, protein translation, redox balance, and a host of metabolic pathways . In this context, mitochondrial Hsp90s, including TRAP-1, preserve the association of the first enzyme of glycolysis, hexokinase II (HK-II) to the organelle outer membrane , and ensure the folding/stability of the oxidative phosphorylation complex II subunit , succinate dehydrogenase, SDHB . These functions are important for cellular homeostasis, because targeting TRAP-1 by pharmacologic or genetic approaches irreversibly compromises mitochondrial integrity, impairs both glycolysis and oxidative phosphorylation , and may provide a novel anticancer strategy in humans (Altieri et al., 2012) .
However, how TRAP-1 regulation of mitochondrial homeostasis fits with general mechanisms of tumor metabolic reprogramming has not been clearly delineated. Known as the ''Warburg effect'' , most tumors rewire their energy sources toward aerobic glycolysis and at the expense of mitochondrial respiration (Wallace, 2012). Together with the identification of mutations in oxidative phosphorylation subunits that produce ''oncometabolites'' Turcan et al., 2012) or stabilize oncogenes, such as HIF1a , this has suggested that mitochondrial bioenergetics has limited (if any) role in cancer ) and may actually function as a ''tumor suppressor'' (Frezza et al., 2011) . In this context, the role of mitochondrial Hsp90s in bioenergetics has become controversial, as conflicting reports in the literature have claimed that TRAP-1 actually inhibits SDHB activity in tumor cells, promoting the accumulation of the oncometabolite, succinate (Sciacovelli et al., 2013) , or, conversely, acts as a potential ''tumor suppressor'' through stimulation of glucose metabolism ).
To clarify mechanisms of metabolic rewiring in mitochondria, and conclusively elucidate the function of mitochondrial Hsp90s in bioenergetics, we have now generated TRAP-1 knockout mice.
RESULTS

Generation of TRAP-1 Knockout Mice
Using gene-trap technology, we obtained mouse ES cells in which a b-galactosidase gene disrupts the TRAP-1 locus on chromosome 16, downstream of exon 1 ( Figure 1A) . Transfer of TRAP-1-targeted zygotes into C57Bl/6 pseudopregnant recipient mice generated TRAP-1 knockout animals. In genotyping experiments, PCR products of 565 nt, or, conversely, 1,148 nt identified the wild-type (WT) TRAP-1 allele or the b-galactosidase (LacZ)-containing allele, respectively ( Figure 1B) . TRAP-1 knockout (TRAP-1 À/À ) mice were born viable, fertile, and at expected Mendelian rates for both genders. Analysis of tissues from TRAP-1 À/À mice, including liver, kidney, uterus, spleen, brain, heart, and testis confirmed the absence of TRAP-1 protein, compared to WT littermates, by western blotting ( Figure 1C ). Histologic analysis of 15-month-old TRAP-1 À/À mice revealed significantly reduced incidence of multiple age-associated pathologies. Compared to age-matched WT littermates, these included lower body weight ( Figure 1D ) and organ (liver, spleen) hyperplasia ( Figure S1A ), decreased chronic inflammatory infiltrates in lung, stomach, pancreas, and small intestine ( Figure S1B ), lower hepatic lipidosis (Figure S1C) , and reduced pancreatic fibrotic degeneration ( Figure S1B ). Two out of three WT mice examined at this age harbored spontaneous tumors or dysplastic lesions, including bronchoalveolar adenoma, dental dysplasia, and histiocytic sarcoma (Figures S1D-S1H ). In contrast, no tumors or dysplasia were detected in age-matched TRAP-1 À/À mice. In terms of blood chemistry parameters, a complete blood count was unremarkable between the various animal groups ( Figure S1I ), whereas TRAP-1 À/À mice showed decreased blood levels of glucose (see below) and creatinine, compared to WT animals ( Figure S1J ). We next profiled signaling pathways in WT or TRAP-1 À/À mice by Reverse Phase Protein Array (RPPA). Consistent with a role of mitochondria in ''retrograde'' signaling and nuclear gene expression (Butow and Avadhani, 2004) , TRAP-1 deletion was associated with general reduction in growth factor receptor activity (MIG6, Her3, EGFR, MEK2, and PI3K), attenuated TGFb responses (Smad1 and Smad3), modulation of cell-cell and cellmatrix communication (N-cadherin, E-cadherin, b-catenin, transglutaminase, fibronectin), and stimulation of cell-cycle transitions (p21, Rb1, E2F1, cyclin E1, PCNA) ( Figure 1E ). TRAP-1 deficiency also profoundly affected bioenergetics pathways. Consistent with recent observations , TRAP-1 loss resulted in significantly reduced levels of mitochondrial complex II subunit, SDHB ( Figure 1E ). This was associated with reduced expression of fatty acid synthase and mitochondrial complex IV subunit, Cox-IV, upregulation of complex V subunit, ATP5H, and higher levels of the glycolytic enzyme, G6PD ( Figure 1E ). Decreased Cox-IV expression in TRAP-1 À/À mice versus WT samples was confirmed by western blotting ( Figure 1F ). In addition, liver extracts of TRAP-1 À/À mice showed increased recruitment of cytoprotective chaperones Hsp90 and Hsp27 to mitochondria, whereas levels of Hsp70, Hsp60, or VDAC were unchanged in WT or TRAP-1 À/À mice ( Figure 1F ).
Requirement of TRAP-1 for Mitochondrial Oxidative Phosphorylation
To examine a role of TRAP-1 in cellular respiration (Chae et al., 2013), we next used purified mitochondria from primary hepatocytes ( Figure S2A ) and nontransformed mouse embryonic fibroblasts (MEFs) ( Figure S2B ). In these experiments, citrate synthase-normalized ( Figure S2C ) mitochondrial complex I activity was not significantly different between WT and TRAP-1 À/À mice (Figure 2A ), as assessed in three independent mitochondrial preparations ( Figure 2B ). Complex II activity, which was proposed to be inhibited by TRAP-1 (Sciacovelli et al., 2013) , was instead unchanged between the two animal groups ( Figures 2C and 2D ). In addition, treatment with Gamitrinib, a small molecule antagonist that target TRAP-1/Hsp90 selectively in mitochondria , inhibited complex II activity in WT mitochondria but had no effect on TRAP-1 À/À samples (Figure 2E) , consistent with the absence of its target, TRAP-1, in these cells. Conversely, mitochondria isolated from TRAP-1
hepatocytes showed significantly increased activity of complex III ( Figures 2F and 2G ), as well as complex IV ( Figures 2H and  2I ), compared to WT samples. Consistent with these data, mitochondrial respiration was deregulated in TRAP-1 À/À mice and resulted in aberrantly increased oxygen consumption levels, compared to WT cultures ( Figure 2J ).
The mechanistic underpinning of deregulated cellular respiration in TRAP-1 knockout mice was further investigated. Accordingly, deletion of TRAP-1 resulted in a global compensatory upregulation of an oxidative phosphorylation ''transcriptome,'' with increased expression of virtually every subunit of mitochondrial respiration complexes (Figures S2D-S2H ). Compared to WT littermates, this included an average fold increase of 1.31 ± 0.03 (n = 33) for complex I subunits, 1.42 ± 0.081 (n = 4) for complex II, 1.36 ± 0.025 (n = 7) for complex III, and 1.3 ± 0.06 (n = 24) for complex V ( Figures S2D-S2F and S2H ). Two subunits in complex IV, Cox4i2 and Cox6b2, increased by approximately 4-and 20-fold, respectively, in TRAP-1 À/À mice, compared to WT littermates, by array analysis (Figure S2G ), as well as quantitative RT-PCR ( Figure S2I ), resulting in a 2.86 ± 1.34 (n = 15) average fold increase for all complex IV subunits. In contrast, overall mitochondrial DNA content was unchanged in WT or TRAP-1 À/À mice ( Figure S2J ).
Glycolytic Reprogramming in TRAP-1 Knockout Mice
In addition to mitochondrial oxidative phosphorylation, TRAP-1 has been linked to the regulation of glycolysis (Chae et al., (Figure 1F) . Second, we established clones of cervical carcinoma HeLa cells selected for stable small hairpin RNA (shRNA) knockdown of TRAP-1 ( Figure S4F ). Analysis of these cells also revealed compensatory metabolic reprogramming, with increased oxygen consumption ( Figure S4G ), and higher ATP production ( Figure S4H ), compared to shRNA controls, in a response that correlated with the degree of TRAP-1 depletion ( Figure S4F ).
TRAP-1 Regulation of Oxidative Damage
Deregulated mitochondrial function as observed in TRAP-1 À/À cells may result in oxidative stress, and this possibility was next investigated. In these experiments, TRAP-1 À/À MEFs exhibited a modest, but significant increased production of reactive oxygen species (ROS), compared to WT cultures (Figures 4A and S4I) . TRAP-1 deletion also resulted in consistently higher ROS production in response to increasing oxidative stress (H 2 O 2 ), compared to WT cultures ( Figure S4J ). Consistent with increased sensitivity to oxidative damage, TRAP-1 KO cells stained positive for markers of a DNA damage response, as reflected by increased reactivity for phosphorylated H2AX (gH2AX) (Figures 4B and 4C ). Under these conditions, TRAP-1 À/À MEFs exhibited profound defects in cell proliferation compared to WT cultures ( Figure 4D ), coinciding with cell-cycle arrest at G2/M ( Figure 4E ), and accumulation of mitotic cyclin B1 ( Figure 4F ). In contrast, the expression of cyclin A or Cdk2 was unchanged, and p21 levels were reduced in TRAP-1 À/À MEFs ( Figure 4G ), consistent with the data of RPPA profiling ( Figure 1D ).
DISCUSSION
In this study, we have shown that homozygous deletion of the mitochondrial chaperone TRAP-1 causes global reprogramming of cellular bioenergetics, with compensatory upregulation of oxidative phosphorylation and glycolysis transcriptomes, increased mitochondrial accumulation of cytoprotective chaperones Hsp90 and Hsp27, and a dramatic switch to glycolytic metabolism, in vivo. This is accompanied by reduced incidence of age-associated pathologies, in vivo, including obesity, dysplasia and tumor formation, decreased cell proliferation, and low-level ROS production. The data presented here refute recent and contradictory claims that TRAP-1 inhibits mitochondrial SDHB-complex II activity (Sciacovelli et al., 2013) , or, conversely, promotes glycolysis . These preliminary suggestions were at odd with a large body of literature, in which pharmacologic or genetic targeting of TRAP-1 inhibited mitochondrial respiration (Butler et al., 2012; Chae et al., 2013) , impaired mitochondrial quality control (Costa et al., 2013) , caused oxidative damage (Butler et al., 2012; Pridgeon et al., 2007) , and suppressed ATP production (Agorreta et al., 2014; Chae et al., 2012) . Consistent with this model, we found that homozygous deletion of TRAP-1 resulted in decreased SDHB expression, reflecting loss of protein-folding quality control in mitochondria . Mechanistically, this role of TRAP-1 in organelle protein homeostasis ) emerged here as a critical requirement for mitochondrial bioenergetics. Accordingly, a compensatory upregulation of virtually every effector of oxidative phosphorylation and glycolysis in TRAP-1 À/À mice was sufficient to restore complex II activity, increase mitochondrial respiration through At variance with recent claims of TRAP-1 as a ''tumor suppressor'' , older TRAP-1 À/À mice were instead significantly healthier than their age-matched WT littermates, with significantly reduced obesity, inflammatory and degenerative pathologies, or spontaneous dysplastic lesions, including tumor formation. More work is required to conclusively dissect the observed phenotype. However, increased mitochondrial respiration, as paradoxically induced as compensation for TRAP-1 loss (this study), has been associated with extended lifespan in model organisms (Guarente, 2008) , potentially contributing to the increased longevity afforded by calorie restriction (Nisoli et al., 2005) . In this context, low levels of mitochondrial respiration-derived ROS, as demonstrated here in TRAP-1 À/À mice, may activate ''retrograde'' gene expression mechanisms of adaptation and cytoprotection (Merksamer et al., 2013 ) and exert beneficial effects in aging (Schulz et al., 2007) . In addition, the combination of a chronic DNA damage response, which opposes malignant transformation (Gorgoulis et al., 2005) , and impaired proliferative capacity, as observed here in TRAP-1 À/À cells, may further preserve organ integrity during aging.
A pivotal function of TRAP-1 in mitochondrial homeostasis, as reinforced here, suggests that models of extramitochondrial bioenergetics, i.e., aerobic glycolysis (Ward and Thompson, 2012) may not fully recapitulate the complexity of metabolic reprogramming in tumors . In this context, TRAP-1-directed mitochondrial metabolism may be important to support highly energy-demanding traits of tumor cells, for instance, cell invasion (Caino et al., 2013) or cell proliferation (this study), especially under conditions of chronic nutrient deprivation. In parallel, ATP produced under these conditions may blunt tumor suppression mechanisms driven by AMPK activation (Liang and Mills, 2013) , escape autophagic cell death (Kimmelman, 2011) , and preserve mTOR signaling (Guertin and Sabatini, 2007) , all key requirements of tumor progression, in vivo. Consistent with this view, oxidative phosphorylation is being increasingly recognized as a key requirement of aggressive tumor behavior, preserving a cancer stem cell phenotype (Janiszewska et al., 2012) , and promoting drug resistant disease . Together with its broad cytoprotective functions, these properties make TRAP-1 a uniquely attractive therapeutic target in cancer, suitable to disable multiple pathways of bioenergetics, cell survival, and adaptation in genetically heterogeneous tumors (Altieri et al., 2012) . Following pronuclear injections, zygotes were transferred to pseudopregnant C57BL/6 female mice and resulting chimeric male mice were crossed with C57BL/6 females to obtain mice heterozygous for the insertional mutation. The colony was maintained on a mixed B6/129 background by brother 3 sister mating.
Statistical Analysis
Data were analyzed using the two-sided unpaired t tests using a GraphPad software package (Prism 4.0) 
